Overview

Study to Assess PK, Safety and Tolerability Early in Healthy Subjects

Status:
COMPLETED
Trial end date:
2023-01-06
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of QHRD106 early in Chinese healthy subjects with single doses.
Phase:
PHASE1
Details
Lead Sponsor:
Changzhou Qianhong Bio-pharma Co., Ltd.